Lifesaving liver disease medicines

Our mission

Versantis develops a new generation of liver disease therapeutics and diagnostics.

We are committed to the translation of life-saving therapies for acute hepatic diseases, where the medical need is dramatically high.

A life-saving therapy

Versantis’ lead product candidate, VS-01, is being advanced into a Phase 2a clinical trial for the treatment of Acute-on-Chronic Liver Failure (ACLF). VS-01 was granted orphan drug designations from both FDA and EMA and has the potential to target the liver deficiencies associated with high unmet need and cost of care, such as acute hepatic encephalopathy (acute HE), ACLF, cirrhosis decompensation,or urea cycle disorders (UCDs). The versatile mechanism of action of VS-01 can simultaneously support multiple affected organ functions (liver, kidneys, brain), encourage liver regeneration, and save patients’ lives.

discover the full potential of our pipeline...

Awards and supports



Versantis AG
Technoparkstrasse 1
CH-8005 Zurich


Copyright © 2021
Versantis AG